Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in the USA / NCT07816692
Recruiting Observational

iDose TR Administration in an Office-Based Surgery Setting

NCT07816692 · tracked via the Priya Life Science USA tracker
Sponsor
Glaukos Corporation
Phase
Observational
Started
2026-05-13
Last updated
2026-09-30

Condition(s) studied

Open Angle Glaucoma (OAG)Ocular Hypertension (OHT)

Investigational drug(s) / intervention(s)

iDose TR (travoprost intracameral implant) 75 µg

iDose TR (travoprost intracameral implant) 75 µg: Travoprost-releasing implant preloaded in a sterile, single-use inserter.

Study summary

Clinical in-use observational trial to evaluate the administration of iDose TR (travoprost intracameral implant) in an office-based surgery setting.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Diagnosis of Open angle glaucoma (OAG) or ocular hypertension (OHT) Exclusion Criteria: * Prior administration of iDose TR or administration of an investigational intracameral implant in the study eye * Active ocular infection or inflammation * History of hypersensitivity to travoprost or implant components * Recent ocular surgery * Uncontrolled systemic disease * Any condition preventing safe implantation

Primary outcome measure(s)

  • Successful administration of iDose TR in an office-based surgical setting. — 3 months
    Number of subjects that received iDose TR in an office-based surgical setting by the Investigator.

Trial sites (1)

FacilityCityRegionStatus
Glaukos Investigative Site Austin Texas Recruiting

More Glaukos Corporation trials in the USA

A Study to Evaluate the Safety and Efficacy of NEXAGON® (Lufepirsen Ophthalmic Gel) in Subjects With PCED Recruiting
Glaukos® iStent Infinite Trabecular Micro-Bypass System in Subjects With Mild to Moderate Primary Open-angle Glaucoma Recruiting
Travoprost Intraocular Implant + iStent Infinite Recruiting
Evaluate the Safety and Feasibility of Same-Day Bilateral Epithelium-On Corneal Cross-Linking for Keratoconus Recruiting
Placebo-controlled Study to Evaluate the Safety and Efficacy of GLK-221 Ophthalmic Solution in Subjects With Keratoconus Recruiting

Other trials for the same condition

REGN22530 for Adults With Primary Open Angle Glaucoma or Ocular Hypertension Recruiting
Observational Trial of the Updated Inserter for the Travoprost Intracameral Implant 75mcg Recruiting
Safety and Efficacy of iDose® TR With Cataract Surgery vs. Cataract Surgery Alone Recruiting
Safety and Effectiveness of the VisiPlate Aqueous Shunt in Patients With Refractory Open-Angle Glaucoma Recruiting
Evaluating ER-100 for Safety in People With Glaucoma or Non-Arteritic Anterior Ischemic Optic Neuropathy (Optic Nerve Conditions) Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07816692 on ClinicalTrials.gov ↗ ← All trials in the USA